Martin Berk, MD
Advanced Heart Failure and Transplant Cardiology · Dallas, TXNPI 1033118278
Payments from drug & device makers
Across 1,226 payments — averaging $1521.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$342K
- Janssen Research & Development, LLC$247K
- American Regent$196K
- Novartis$171K
- Johnson & Johnson$119K
- Novo Nordisk$116K
- plus $674K from 29 others
Across 3 payments — averaging $1086.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$3K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 563 | $342,359 |
| Janssen Research & Development, LLC | 53 | $247,077 |
| American Regent | 20 | $195,908 |
| Novartis | 39 | $171,053 |
| Johnson & Johnson | 110 | $118,780 |
| Novo Nordisk | 61 | $115,694 |
| AstraZeneca | 12 | $100,387 |
| Merck | 71 | $82,140 |
| Cvrx, Inc. | 23 | $81,659 |
| Regeneron | 30 | $65,310 |
| Bayer | 43 | $63,969 |
| Eli Lilly | 8 | $62,990 |
| Pfizer | 21 | $59,745 |
| Boehringer Ingelheim International GmbH | 48 | $56,977 |
| Amgen | 22 | $42,769 |
| Boehringer Ingelheim | 30 | $27,600 |
| Lilly USA, LLC | 10 | $8,877 |
| Amarin Pharma, Inc. | 3 | $6,890 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 1 | $6,506 |
| Esperion Therapeutics, Inc. | 5 | $5,938 |
| Boston Scientific | 11 | $712 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 14 | $336 |
| Heartflow, Inc. | 3 | $263 |
| Abbott | 2 | $193 |
| Inspire Medical Systems, Inc. | 1 | $145 |
| Idorsia Pharmaceuticals US Inc | 2 | $121 |
| Kestra Medical Technology Services, Inc. | 3 | $95 |
| Sanofi-aventis U.S. LLC | 5 | $76 |
| E.r. Squibb & Sons, L.L.C. | 4 | $74 |
| Itamar Medical Inc | 2 | $46 |
| Bard Peripheral Vascular, Inc. | 1 | $42 |
| Siemens Medical Solutions USA, Inc. | 2 | $32 |
| Lexicon Pharmaceuticals, Inc. | 1 | $23 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $19 |
| Scpharmaceuticals Inc. | 1 | $19 |
How this compares
$1,864,824 in reported general payments places this provider in the 95th percentile of 75 advanced heart failure and transplant cardiology providers in Texas.
See all advanced heart failure and transplant cardiology providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other advanced heart failure and transplant cardiology in Dallas
- Robert GottliebDallas$14.1M
- Shelley HallDallas$1.3M
- Elizabeth HardinDallas$571K
- Claudius MahrDallas$331K
- Maryjane FarrDallas$304K
- Katherine MichelisDallas$187K
- Kartik TelukuntlaDallas$80K
- Song LiDallas$27K
- Farah Al-SaffarDallas$24K
- Srikant PatlollaDallas$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.